NCT01486329已完成1 期
VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer to Examine Safety, Tolerability, and Immune Response to the Investigational VEGFR-2 DNA Vaccine VXM01
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Vaximm GmbH
- 入组人数
- 72
- 试验地点
- 2
- 主要终点
- Safety and tolerability
研究概览
简要总结
First-in-human phase I dose escalation study in patients with locally advanced, inoperable and stage IV pancreatic cancer to examine safety, tolerability, and immune response to the investigational VEGFR-2 DNA vaccine VXM01 to examine safety and tolerability, clinical and immunogenic response to the investigational vascular endothelial growth factor receptor 2 (VEGFR-2) DNA vaccine VXM01, and to define the maximum tolerated dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent, signed and dated
- •Locally advanced, inoperable and stage IV pancreatic cancer patients according to UICC based on diagnostic imaging using computer-tomography (CT) or histological examinations
- •Male or post-menopausal female
- •Age above or equal to 18 years
- •Chemotherapy naïve within 60 days before screening visit except gemcitabine treatment
- •Karnovsky index >70
- •Life expectancy >3 months
- •Adequate renal, hepatic, and bone marrow function
- •Absolute neutrophil count >1500/µL
- •Hemoglobin >10 g/dL
- •Platelets >75000/µL
- •Prothrombin time and international normalized ratio (INR) <1.5 times upper limit of normal (ULN) (except under anticoagulant treatment)
- •Aspartate aminotransferase <4 times ULN
- •Alanine aminotransferase <4 times ULN
- •Total bilirubin <3 times ULN
- •Creatinine clearance estimated according to Cockcroft-Gault >30 mL/min
- •Proteinuria <1 g protein on 24 h urine collection
排除标准
- •State after pancreas resection (complete or partial)
- •Resectable disease
- •Drug trial participation within 60 days before screening visit
- •Other previous or current malignancy except basal or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for <2 years
- •Prior vaccination with Ty21a
- •Cardiovascular disease defined as:
- •Uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg)
- •Arterial thromboembolic event within 6 months before randomization including:
- •Myocardial infarction
- •Unstable angina pectoris
- •Cerebrovascular accident
- •Transient ischemic attack
- •Congestive heart failure New York Heart Association grade III to IV
- •Serious ventricular arrhythmia requiring medication
- •Clinically significant peripheral artery disease > grade 2b according to Fontaine
- •Hemoptysis within 6 months before randomization
- •Esophageal varices
- •Upper or lower gastrointestinal bleeding within 6 months before randomization
- •Significant traumatic injury within 4 weeks before randomization
- •Non-healing wound, bone fracture or any history of gastrointestinal ulcers within three years before inclusion, or positive gastroscopy within 3 months before inclusion
- •Gastrointestinal fistula
- •Thrombolysis therapy within 4 weeks before randomization
- •Bowel obstruction within the last 30 days before screening visit
- •Liver cirrhosis ≥ grade B according to Child-Pugh Score-Classification
- •Presence of any acute or chronic systemic infection
- •Radiotherapy within 4 weeks before randomization
- •Major surgical procedures, or open biopsy within 4 weeks before randomization
- •Fine needle aspiration within 7 days before randomization
- •Chronic concurrent therapy within 2 weeks before and during the double-blind study period with:
- •Corticosteroids (except steroids for adrenal failure) or immunosuppressive agents
- •Antibiotics
- •Bevacizumab
- •Any epidermal growth factor receptor inhibitor
- •Chemotherapy except gemcitabine before Day 10
- •Multi-drug resistant gram-negative germ
- •Pregnancy
- •Lactation
- •Inability to comply with study and/or follow-up procedures
- •History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the study results or render the patient at high risk for treatment complications
- •Women of childbearing potential
- •Any history of drug hypersensitivity
- •Any condition which results in an undue risk for the patient during the study participation according to the investigator
结局指标
主要结局
Safety and tolerability
时间窗: 38 days
Number of dose-limiting toxicities and maximum tolerated dose
次要结局
- Immune response(Up to 24 months)
- Tumor perfusion(Up to 24 months)
- Tumor staging(Up to 24 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
VXM01 phase I dose escalation study in patients with locally advanced, inoperable and stage IV pancreatic cancerCancerISRCTN68809279VAXIMM GmbH (Germany)72
已完成
1 期
Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid TumorsNeoplasmsCancerNCT01514123Circadian Technologies Ltd.43
已完成
1 期
A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid TumorsMalignant Solid TumorNCT03192345Sanofi161
已完成
1 期
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or LymphomasSquamous Cell Carcinoma of the Head and NeckNon Small Cell Lung CancerUrothelial CarcinomaGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaSquamous Cell Carcinoma of the AnusSquamous Cell Carcinoma of the CervixSquamous Cell Carcinoma of the SkinDiffuse Large B Cell LymphomaMismatch Repair Deficient or MSI-High Solid TumorsMelanomaRenal Cell CarcinomaHodgkin LymphomaNCT03894618Shattuck Labs, Inc.49
Unknown
1 期
A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid TumorsAdvanced Solid TumorNCT05258266Nanjing Zenshine Pharmaceuticals76